ZimVie (ZIMV) Projected to Post Earnings on Thursday

Key Points

• ZimVie is projected to release its Q2 2025 earnings on Thursday, August 7th, with analysts expecting earnings of $0.23 per share and revenue of $112.82 million.
• The company reported a negative net margin of 4.40% and a positive return on equity of 5.53% in its last earnings release.
• Analysts have a consensus rating of "Moderate Buy" for ZimVie, with an average target price of $17.00, indicating varied outlooks among several research analysts.

ZimVie (NASDAQ:ZIMV - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of $0.23 per share and revenue of $112.82 million for the quarter.

ZimVie (NASDAQ:ZIMV - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.26 earnings per share (EPS) for the quarter. ZimVie had a negative net margin of 4.39% and a positive return on equity of 6.37%. The company had revenue of $116.66 million during the quarter, compared to analysts' expectations of $112.60 million.

ZimVie Stock Performance

ZIMV traded down $0.03 on Friday, reaching $18.76. The company had a trading volume of 514,225 shares, compared to its average volume of 1,154,339. The stock has a market cap of $522.47 million, a P/E ratio of -26.80 and a beta of 2.19. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.48 and a current ratio of 2.37. ZimVie has a fifty-two week low of $8.15 and a fifty-two week high of $19.44. The company's fifty day moving average is $11.07 and its 200 day moving average is $11.27.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. UBS Group lowered their target price on ZimVie from $16.00 to $10.00 and set a "neutral" rating on the stock in a research note on Thursday, May 15th. B. Riley cut ZimVie from a "buy" rating to a "neutral" rating and set a $19.00 price objective on the stock. in a research report on Thursday. Needham & Company LLC reissued a "hold" rating on shares of ZimVie in a research report on Wednesday, April 9th. Wall Street Zen downgraded shares of ZimVie from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Finally, Barclays raised shares of ZimVie from an "underweight" rating to an "equal weight" rating and raised their price target for the stock from $9.00 to $19.00 in a research report on Tuesday, July 22nd. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $17.75.

Hedge Funds Weigh In On ZimVie

A number of hedge funds have recently added to or reduced their stakes in ZIMV. Goldman Sachs Group Inc. increased its stake in ZimVie by 2.3% in the first quarter. Goldman Sachs Group Inc. now owns 133,611 shares of the company's stock valued at $1,443,000 after acquiring an additional 3,043 shares during the last quarter. Jones Financial Companies Lllp increased its stake in shares of ZimVie by 9,039.1% in the 1st quarter. Jones Financial Companies Lllp now owns 12,612 shares of the company's stock valued at $136,000 after purchasing an additional 12,474 shares during the last quarter. Jane Street Group LLC raised its holdings in shares of ZimVie by 69.6% during the 1st quarter. Jane Street Group LLC now owns 32,031 shares of the company's stock worth $346,000 after buying an additional 13,150 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of ZimVie by 53.4% during the 1st quarter. AQR Capital Management LLC now owns 103,820 shares of the company's stock worth $1,115,000 after buying an additional 36,132 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of ZimVie by 7.7% during the 1st quarter. Millennium Management LLC now owns 707,771 shares of the company's stock worth $7,644,000 after buying an additional 50,805 shares during the last quarter. Institutional investors own 95.63% of the company's stock.

About ZimVie

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.